Targeting RAS-Driven PI3Kα Activation in Human Tumors

Bridgebio Oncology Therapeutics Inc. published this content on December 07, 2023, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on September 25, 2025 at 12:20 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]